LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

Biogen Inc

Отворен

СекторЗдравеопазване

137.8 0.28

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

135.28

Максимум

137.65

Ключови измерители

By Trading Economics

Приходи

394M

635M

Продажби

215M

2.6B

P/E

Средно за сектора

13.46

35.69

EPS

3.02

Марж на печалбата

23.995

Служители

7,605

EBITDA

457M

1B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+21.72% upside

Дивиденти

By Dow Jones

Следващи печалби

29.10.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.9B

21B

Предишно отваряне

137.52

Предишно затваряне

137.8

Настроения в новините

By Acuity

50%

50%

131 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

Biogen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.09.2025 г., 18:25 ч. UTC

Значими двигатели на пазара

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

28.09.2025 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise After Friday's Stock Gains on Wall Street -- Market Talk

28.09.2025 г., 23:48 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

28.09.2025 г., 23:45 ч. UTC

Пазарно говорене

Gold Rises Amid Fed Rate-Cut Hopes -- Market Talk

28.09.2025 г., 23:34 ч. UTC

Пазарно говорене

Oil Falls on Likely Technical Correction -- Market Talk

27.09.2025 г., 04:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

26.09.2025 г., 21:56 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26.09.2025 г., 20:54 ч. UTC

Печалби

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

26.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

26.09.2025 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26.09.2025 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

26.09.2025 г., 19:54 ч. UTC

Пазарно говорене

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26.09.2025 г., 19:53 ч. UTC

Придобивния, сливания и поглъщания

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26.09.2025 г., 19:40 ч. UTC

Печалби

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26.09.2025 г., 19:24 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26.09.2025 г., 19:17 ч. UTC

Пазарно говорене

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26.09.2025 г., 19:15 ч. UTC

Пазарно говорене

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26.09.2025 г., 19:03 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

26.09.2025 г., 19:03 ч. UTC

Пазарно говорене

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26.09.2025 г., 18:50 ч. UTC

Пазарно говорене
Печалби

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26.09.2025 г., 18:36 ч. UTC

Пазарно говорене

Silver Closes Out Week With Strong Surge -- Market Talk

26.09.2025 г., 18:02 ч. UTC

Придобивния, сливания и поглъщания

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26.09.2025 г., 18:02 ч. UTC

Придобивния, сливания и поглъщания

ING: Global Development Hasn't Received All Necessary Approvals >ING

26.09.2025 г., 18:02 ч. UTC

Придобивния, сливания и поглъщания

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26.09.2025 г., 17:54 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26.09.2025 г., 16:56 ч. UTC

Пазарно говорене
Печалби

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26.09.2025 г., 16:41 ч. UTC

Пазарно говорене
Печалби

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26.09.2025 г., 16:26 ч. UTC

Печалби

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26.09.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Biogen Inc Прогноза

Ценова цел

By TipRanks

21.72% нагоре

12-месечна прогноза

Среден 167.2 USD  21.72%

Висок 224 USD

Нисък 118 USD

Според 26 анализатори от Wall Street, предложили 12-месечна ценова цел за Biogen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

26 ratings

12

Купи

14

Задържане

0

Продай

Техническа оценка

By Trading Central

118.15 / 121.17Подкрепа & съпротива

Краткосрочен план

Weak Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

131 / 371 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat